These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11417113)

  • 1. Purine analogs as CDK enzyme inhibitory agents: a survey and QSAR analysis.
    Lee AD; Ren S; Lien EJ
    Prog Drug Res; 2001; 56():155-93. PubMed ID: 11417113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
    Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
    Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.
    Ruetz S; Fabbro D; Zimmermann J; Meyer T; Gray N
    Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):1-14. PubMed ID: 12678910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
    Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
    J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
    Haesslein JL; Jullian N
    Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
    Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
    Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
    Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
    J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design and synthesis of purine inhibitors of CDK2. III.
    Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
    Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
    Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
    Ducrot P; Legraverend M; Grierson DS
    J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
    Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
    J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
    Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
    J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases.
    Mayi T; Facca C; Anne S; Vernis L; Huang ME; Legraverend M; Faye G
    J Biotechnol; 2015 Feb; 195():30-6. PubMed ID: 25541464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
    De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
    Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
    Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
    J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives as cyclin-dependent kinase inhibitors. Part II.
    Oh CH; Kim HK; Lee SC; Oh C; Yang BS; Rhee HJ; Cho JH
    Arch Pharm (Weinheim); 2001 Nov; 334(11):345-50. PubMed ID: 11822171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-site directed inhibitors of cyclin-dependent kinases.
    Gray N; Détivaud L; Doerig C; Meijer L
    Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.